Jubilant Life Sciences surge on receiving EIR

Jubilant Life Sciences informed the bourses on Tuesday that its subsidiary, Jubilant Pharma, through one of its wholly-owned subsidiaries, has received an establishment inspection report (EIR) with voluntary action indicated (VAI) status from USFDA for its solid dosage facility at Salisbury, Maryland USA in respect to the inspection conducted by the regulatory agency from February 24 to 28, 2020. The company further said that with the receipt of this EIR, the inspection stands successfully closed.

With response to this development, the stock of Jubilant Life Sciences opened gap up at Rs 263.80 as against the previous close of Rs 248.85 apiece. The stock continues to trade in a positive terrain whereas; the major benchmark indices were trading in a negative terrain. At 10.57 am, the stock was trading at Rs 255, up by nearly 2.5 per cent.

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life science company engaged in pharmaceuticals, life science ingredients, drug discovery and development solution business.